Portage Biotech (NASDAQ:ATON) Trading 3.8% Higher – What’s Next?

Shares of Portage Biotech Inc. (NASDAQ:ATON) traded up 3.8% during mid-day trading on Tuesday . The company traded as high as $0.3504 and last traded at $0.3320. 9,777,470 shares traded hands during mid-day trading, an increase of 209% from the average session volume of 3,165,393 shares. The stock had previously closed at $0.32.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Weiss Ratings assumed coverage on Portage Biotech in a research report on Monday, January 26th. They issued a “sell (e+)” rating on the stock. HC Wainwright assumed coverage on Portage Biotech in a research report on Tuesday, February 24th. They issued a “buy” rating and a $2.00 price objective on the stock. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $2.00.

Portage Biotech Stock Performance

The stock has a market capitalization of $7.78 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. The business’s 50 day simple moving average is $0.35.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.